Literature DB >> 17442937

Characterization of human lung tumor-associated fibroblasts and their ability to modulate the activation of tumor-associated T cells.

Michael R Nazareth1, Lori Broderick, Michelle R Simpson-Abelson, Raymond J Kelleher, Sandra J Yokota, Richard B Bankert.   

Abstract

The tumor microenvironment of human non-small cell lung cancer (NSCLC) is composed largely of stromal cells, including fibroblasts, yet these cells have been the focus of few studies. In this study, we established stromal cell cultures from primary NSCLC through isolation of adherent cells. Characterization of these cells by flow cytometry demonstrated a population which expressed a human fibroblast-specific 112-kDa surface molecule, Thy1, alpha-smooth muscle actin, and fibroblast activation protein, but failed to express CD45 and CD11b, a phenotype consistent with that of an activated myofibroblast. A subset of the tumor-associated fibroblasts (TAF) was found to express B7H1 (PD-L1) and B7DC (PD-L2) constitutively, and this expression was up-regulated by IFN-gamma. Production of cytokines and chemokines, including IFN-gamma, monokine induced by IFN-gamma, IFN-gamma-inducible protein-10, RANTES, and TGF-beta1 was also demonstrated in these cells. Together, these characteristics provide multiple opportunities for the TAF to influence cellular interactions within the tumor microenvironment. To evaluate the ability of TAF to modulate tumor-associated T cell (TAT) activation, we conducted coculture experiments between autologous TAF and TAT. In five of eight tumors, TAF elicited a contact-dependent enhancement of TAT activation, even in the presence of a TGF-beta1-mediated suppressive effect. In the three other tumors, TAF had a net suppressive effect upon TAT activation, and, in one of these cases, blockade of B7H1 or B7DC was able to completely abrogate the TAF-mediated suppression. We conclude that TAF in human NSCLC are functionally and phenotypically heterogeneous and provide multiple complex regulatory signals that have the potential to enhance or suppress TAT function in the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442937     DOI: 10.4049/jimmunol.178.9.5552

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  93 in total

1.  Differential expression of stem cell markers in human follicular bulge and interfollicular epidermal compartments.

Authors:  Shu Jiang; Longmei Zhao; Bhamini Purandare; Basil M Hantash
Journal:  Histochem Cell Biol       Date:  2010-03-13       Impact factor: 4.304

Review 2.  Mesenchymal cells of the intestinal lamina propria.

Authors:  D W Powell; I V Pinchuk; J I Saada; Xin Chen; R C Mifflin
Journal:  Annu Rev Physiol       Date:  2011       Impact factor: 19.318

3.  T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.

Authors:  Jennifer L Barnas; Michelle R Simpson-Abelson; Sandra J Yokota; Raymond J Kelleher; Richard B Bankert
Journal:  Cancer Microenviron       Date:  2010-03-31

4.  Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.

Authors:  Liang-Chuan S Wang; Albert Lo; John Scholler; Jing Sun; Rajrupa S Majumdar; Veena Kapoor; Michael Antzis; Cody E Cotner; Laura A Johnson; Amy C Durham; Charalambos C Solomides; Carl H June; Ellen Puré; Steven M Albelda
Journal:  Cancer Immunol Res       Date:  2013-11-12       Impact factor: 11.151

5.  CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia.

Authors:  Hadas Lewinsky; Avital F Barak; Victoria Huber; Matthias P Kramer; Lihi Radomir; Lital Sever; Irit Orr; Vita Mirkin; Nili Dezorella; Mika Shapiro; Yosef Cohen; Lev Shvidel; Martina Seiffert; Yair Herishanu; Shirly Becker-Herman; Idit Shachar
Journal:  J Clin Invest       Date:  2018-11-05       Impact factor: 14.808

Review 6.  Bioinformatic approaches to augment study of epithelial-to-mesenchymal transition in lung cancer.

Authors:  Tim N Beck; Adaeze J Chikwem; Nehal R Solanki; Erica A Golemis
Journal:  Physiol Genomics       Date:  2014-08-05       Impact factor: 3.107

Review 7.  Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation.

Authors:  Miguel F Sanmamed; Lieping Chen
Journal:  Cancer J       Date:  2014 Jul-Aug       Impact factor: 3.360

Review 8.  Tumor stroma as targets for cancer therapy.

Authors:  Jing Zhang; Jinsong Liu
Journal:  Pharmacol Ther       Date:  2012-10-12       Impact factor: 12.310

9.  Melanoma-associated fibroblasts modulate NK cell phenotype and antitumor cytotoxicity.

Authors:  Mirna Balsamo; Francesca Scordamaglia; Gabriella Pietra; Claudia Manzini; Claudia Cantoni; Monica Boitano; Paola Queirolo; William Vermi; Fabio Facchetti; Alessandro Moretta; Lorenzo Moretta; Maria Cristina Mingari; Massimo Vitale
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-23       Impact factor: 11.205

10.  Cross-species functional analysis of cancer-associated fibroblasts identifies a critical role for CLCF1 and IL-6 in non-small cell lung cancer in vivo.

Authors:  Silvestre Vicent; Leanne C Sayles; Dedeepya Vaka; Purvesh Khatri; Olivier Gevaert; Ron Chen; Yanyan Zheng; Anna K Gillespie; Nicole Clarke; Yue Xu; Joseph Shrager; Chuong D Hoang; Sylvia Plevritis; Atul J Butte; E Alejandro Sweet-Cordero
Journal:  Cancer Res       Date:  2012-09-07       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.